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S192 Oral PresentationsMultiple investigators have determined that the average bio-
availability of oral busulfan is estimated to be 70-80%. Based
upon the established 1 mg/kg/dose of oral busulfan, the intravenous
equivalent was established at 0.8 mg/kg/dose given every 6 hours.
The primary purpose of this evaluation is to determine if 0.8 mg/
kg is the most appropriate starting dose for all populations and
will reliably provide a therapeutic area under the curve (AUC) for
a majority of the patients. Additionally, this evaluation will review
the effect of using adjusted versus actual body weight for the initial
dosing of busulfan.
A retrospective review was completed in 28 patients that re-
ceived targeted busulfan given every 6 hours as a component of
the Bu/Cy2 preparative regimen for allogeneic transplant from
9/07 to 9/09. Initial busulfan dosing was started at 0.8 mg/kg on
actual body weight unless the patient was. 30% over ideal body
weight and then an adjusted body weight calculation was utilized.
Since our dose adjustments are based on a target AUC of
1100 mMol/min, 61% (17/28) required dose increases. AUC levels
of# 900 mMol/min were observed in 6 out of 28 patients (28%). In
addition, 5 out of the 6 patients that had an AUC# 900 mMol/min
were initially dosed based upon an adjusted body weight. Of all pa-
tients requiring dose increases, 10/17 (59%) were significantly
overweight with a range of 31-112% over ideal body weight.
Only 1 patient (4%) fell into the supratherapeutic range with an
AUC. 1500 mMol/min and this patient was heavily pretreated
and had underlying hepatic dysfunction. See table 1 for summary
of data.
Based upon our data, it appears that we are initially underdosing
busulfan in a number of patients. Further analysis is required before
significant changes are made to our current approach, but our data
suggests that we need to increase our starting dose to at least
0.9 mg/kg/dose in a majority of our patients.
Table 1. Data Summary
Initial TargetedGender
Age
(yr)AUC
(mMol/min)Clearance
(mL/min)/kgActual
weight
(kg)Dosing
weight
(kg)Busulfan
Dose
(mg)Busulfan
Dose
(mg)F 59 823 4 72.7 58.5 47 62
F 37 832 3.9 74.8 59 47 62
M 59 843 3.7 83.6 83 66 86.2
M 47 857 3.8 73.4 62.8 50 64.2
M 50 882 3.7 102 84 56 70
F 42 900 3.6 131 89.3 72 88
M 60 920 3.5 108 88.3 70 83.7
F 48 924 3.5 108 75 60 71.4
M 46 927 3.5 82.7 82.7 66 78
M 57 946 3.4 96.8 96.8 77 89.6
M 49 956 2.9 106 90.3 72 83
M 56 957 3.4 84 84 67 77
M 30 961 3.4 82.3 82.3 66 77.5
M 56 970 2.6 102 84.6 68 77
M 51 1031 3.2 82 82 66 70
F 60 1047 3.1 85 69.5 56 59
M 46 1060 3.1 82.5 82.5 66 68.5
F 45 1081 3 79 65.8 52 52.9
F 49 1117 2.9 62 62 50 49.2
M 51 1152 2.7 100 100 80 76.4
M 47 1193 3.4 85 85 68 62.7
M 52 1196 2.7 100 100 80 74
F 49 1222 2.7 88 68.6 55 50
M 61 1310 2.5 93.8 93.8 75 63
F 53 1367 2.4 56 56 45 36.2
M 56 1423 2.6 91 91 73 56
M 25 1426 2.3 76 76 61 47
F 35 2214 1.5 100 71.5 57 28If dosing weight differs from actual weight, then adjusted body weight
calculation was utilized as follows: adjusted weight5 ideal weight1 0.4
(actual weight – ideal weight).97
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Background:Cyclophosphamide (Cy) (2-7 g/m2) has been shown
to be an effective regimen for hematopoietic stem cell (HSC)
mobilization in multiple myeloma (MM) patients undergoing au-
tologous stem cell transplantation (ASCT). The optimal dose to
be used, which maximizes HSC collection yields while minimiz-
ing febrile neutropenia and other toxicities, remains controver-
sial. Two cohorts of MM patients who received G-CSF and
Cy at dose of either 4 g/m2 (Cy4) or 2 g/m2 (Cy2) were com-
pared.
Methods: 72 patients undergoing first mobilization with Cy and G-
CSFatasingleinstitutionbetween6/06and12/08wereretrospectively
analyzed.TheinitialCy4patientcohort(n5 35)wasmobilizedwithCy
4gm/m2 starting onDay 1 followed byG-CSF(10ug/kg/day) starting
on Day 7 and continuing until completion of apheresis. In 2/08, the
Cy dose was reduced to 2gm/m2 and theG-CSF start date wasmoved
today4(Cy2 n5 37).Minimalandoptimalyieldwasdefinedascollec-
tionof$2106and$6-10106CD34+cells/kgrespectively.Prophy-
lactic antibiotics were given for ANC\500 to reduce risk of febrile
neutropenia.
Results: Minimal cell dose required for ASCT was achieved in
97% vs. 86.5% of Cy4 and Cy2 patients, respectively. Of the 5 pa-
tients failing to mobilize on Cy2, four of these subsequently mo-
bilized adequately following G-CSF and plerixafor. Median
number of apheresis collections required was significantly lower
in the Cy4 patients (1 vs.3, p5 0.0065). The proportion of pa-
tients collecting the minimal and optimal cell dose in 2 or fewer
days of apheresis was 94% vs. 86.5% (p5 0.4304) and 77% vs.
35% (p5 0.0004), in the Cy4 and Cy2 patients respectively. Mo-
bilization with Cy4 was associated with a significantly higher inci-
dence of hospital admissions due to febrile neutropenia (40% vs.
5%, p5 0.0005).
Conclusions: Although Cy4 and Cy2 are both effective HSC
mobilizing regimens, mobilization efficacy and toxicity vary
greatly. Cy4 results in higher HSC yields requiring fewer apheresis
procedures, but this benefit is offset by increased morbidity and
hospitalization. Based on the suboptimal results with Cy 4 g/m2
and Cy 2 g/m2 mobilization, we are currently exploring a chemo-
therapy-free approach utilizing G-CSF +/- plerixafor, with the
aim of optimizing HSC yields while minimizing toxicity and costs.
Patients receive G-CSF(10ug/kg/day), with a day 4 peripheral
CD34+ cell count determining requirement for plerixafor prior
to apheresis.Cy 4gm/m21 Cy 2gm/m21
G-CSF n5 35 G-CSF n5 37 P Value% of Patients who
achieved$ 2 x 106 CD341
cells/kg in# 2 days94% (33/35) 86.5% (32/37) P5 0.4304% of Patients who
achieved$ 6 x 106
CD341cells/kg in# 2 days77% (27/35) 35% (13/37) P5 0.0004% of Patients who
failed to collect$ 2 x 106
CD341 cells/kg2.8%(1/35) 13.5% (5/37) P5 0.1998% of Patients who failed
to achieve$ 6 x106
CD341cells/kg17% (6/35) 37.8% (14/37) P5 0.0668Median (range) days
of collection in all patients1 (1-6) 3 (1-6) P5 0.0065% Patients hospitalized
for febrile neutropenia40% (14/35) 5% (2/37) P5 0.0005
